Frontline Immunotherapy Firmly Established for Select Patients With NSCLC

The use of immunotherapy, either as monotherapy or in combination with chemotherapy, continues to raise the bar with regard to overall survival (OS) benefit in patients with newly diagnosed, advanced nonsquamous non–small cell lung cancer (NSCLC), said Jamie E. Chaft, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center.
... to read the full story